Opus Genetics COO Joseph Schachle sells $13,653 in common stock By Investing.com
- Markets Startups
Peter Lynch- 0
- 3 minutes read
Joseph K. Schachle, Chief Operating Officer at Opus Genetics, Inc. (), recently sold 4,644 shares of the company’s common stock. The transaction, totaling $13,653, occurred on July 23, 2026, with shares sold at a price of $2.94 each. The stock has since risen to $3.35, reflecting a remarkable 161% gain over the past year.
The sale was not a discretionary trade by Mr. Schachle. Instead, the shares were sold automatically by the company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award.
Following this transaction, Mr. Schachle directly holds 291,440 shares of Opus Genetics common stock. According to InvestingPro analysis, the stock is trading near its Fair Value of $3.37, while the platform’s data reveals the company maintains strong liquidity with a current ratio of 7.13. InvestingPro offers 11 additional exclusive tips for IRD investors.
In other recent news, Opus Genetics announced it expects to release three-month topline data from Cohort 1 of its OPGx-BEST1 Phase 1/2 clinical trial in September 2026. This trial is focused on evaluating the safety and efficacy of gene therapy for inherited retinal diseases. Cantor Fitzgerald reiterated an Overweight rating with a $15.00 price target for Opus Genetics, highlighting positive updates from the BIRD-1 trial. Meanwhile, BTIG maintained a Buy rating and set a $12.00 price target, citing progress in gene replacement therapies. The company also reported alignment with the FDA on the Phase 3 trial design for OPGx-LCA5, which has been recognized with Orphan Drug and Rare Pediatric Disease designations. B.Riley reiterated a Buy rating with a $10.00 price target, following this FDA alignment. These developments reflect ongoing advancements in Opus Genetics’ gene therapy programs. The company plans to present data at the EURETINA Congress in Vienna later this year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
investment News
